title: Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.
abstract: Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.
authors.affiliation: Division of Hematology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Kanakry
authors.forename: Yvette L
authors.initials: YL
authors.lastname: Kasamon
authors.forename: Javier
authors.initials: J
authors.lastname: Bolaños-Meade
authors.forename: Ivan M
authors.initials: IM
authors.lastname: Borrello
authors.forename: Robert A
authors.initials: RA
authors.lastname: Brodsky
authors.forename: Ephraim J
authors.initials: EJ
authors.lastname: Fuchs
authors.forename: Nilanjan
authors.initials: N
authors.lastname: Ghosh
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Gladstone
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Gocke
authors.forename: Carol Ann
authors.initials: CA
authors.lastname: Huff
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Kanakry
authors.forename: Leo
authors.initials: L
authors.lastname: Luznik
authors.forename: William
authors.initials: W
authors.lastname: Matsui
authors.forename: Huzefa J
authors.initials: HJ
authors.lastname: Mogri
authors.forename: Lode J
authors.initials: LJ
authors.lastname: Swinnen
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Symons
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Jones
authors.forename: Richard F
authors.initials: RF
authors.lastname: Ambinder
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous / Q000379:methods*; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide
keywords: Allogeneic blood or marrow transplantation; Graft-versus-host disease prophylaxis; Post-transplantation cyclophosphamide; Post-transplantation lymphoproliferative disorder